{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:10:41Z","timestamp":1787857841493,"version":"build-2784847793"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04923-8","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:15:20Z","timestamp":1784610920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug repurposing as a promising therapeutic strategy against renal cell carcinoma"],"prefix":"10.1007","volume":"96","author":[{"given":"Ali","family":"Nakhaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Taghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdieh","family":"Aliyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir R.","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Gheybi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-4593","authenticated-orcid":false,"given":"Mohammad","family":"Jalili-Nik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"4923_CR1","doi-asserted-by":"crossref","unstructured":"Liu J, Li M, Song B, Jia C, Zhang L, Bai X et al (eds) (2013) Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Seminars and Original Investigations, Urologic Oncology2013 Feb;31(2):264-70","DOI":"10.1016\/j.urolonc.2011.01.003"},{"issue":"3","key":"4923_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/biom9030113","volume":"9","author":"M Pasha","year":"2019","unstructured":"Pasha M, Sivaraman SK, Frantz R, Agouni A, Munusamy S (2019) Metformin induces different responses in clear cell renal cell carcinoma caki cell lines. Biomolecules 9(3):113","journal-title":"Biomolecules"},{"issue":"1","key":"4923_CR3","first-page":"1466991","volume":"2022","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li J, Song M, Qi G, Meng L (2022) High-concentration metformin reduces oxidative stress injury and inhibits the growth and migration of clear cell renal cell carcinoma. Comput Math Methods Med 2022(1):1466991","journal-title":"Comput Math Methods Med"},{"issue":"2","key":"4923_CR4","first-page":"2030","volume":"16","author":"J-H Jang","year":"2018","unstructured":"Jang J-H, Song I-H, Sung E-G, Lee T-J, Kim J-Y (2018) Metformin-induced apoptosis facilitates degradation of the cellular caspase 8 (FLICE)-like inhibitory protein through a caspase-dependent pathway in human renal cell carcinoma A498 cells. Oncol Lett 16(2):2030\u20132038","journal-title":"Oncol Lett"},{"issue":"1","key":"4923_CR5","first-page":"7383745","volume":"2022","author":"Y Liu","year":"2022","unstructured":"Liu Y, Meng L-L, Li J-W, Jin Y-S, An R-H (2022) A Randomized Study on the Effect of Metformin Combined with Intensive-Exercise Diet Therapy on Glucose and Lipid Metabolism and Islet Function in Patients with Renal Cell Carcinoma and Diabetes. Dis Markers 2022(1):7383745","journal-title":"Dis Markers"},{"issue":"1","key":"4923_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000441011","volume":"96","author":"C Kalogirou","year":"2016","unstructured":"Kalogirou C, Sch\u00e4fer D, Krebs M, Kurz F, Schneider A, Riedmiller H et al (2016) Metformin-derived growth inhibition in renal cell carcinoma depends on miR-21-mediated PTEN expression. Urol Int 96(1):106\u2013115","journal-title":"Urol Int"},{"key":"4923_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.12659\/MSM.898710","volume":"23","author":"W Xie","year":"2017","unstructured":"Xie W, Wang L, Sheng H, Qiu J, Zhang D, Zhang L et al (2017) Metformin induces growth inhibition and cell cycle arrest by upregulating microRNA34a in renal cancer cells. Med Sci Monitor: Int Med J Experimental Clin Res 23:29","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"issue":"10","key":"4923_CR8","first-page":"3289","volume":"7","author":"F-Q Yang","year":"2014","unstructured":"Yang F-Q, Wang J-J, Yan J-S, Huang J-H, Li W, Che J-P et al (2014) Metformin inhibits cell growth by upregulating microRNA-26a in renal cancer cells. Int J Clin Exp Med 7(10):3289","journal-title":"Int J Clin Exp Med"},{"issue":"9","key":"4923_CR9","first-page":"1504","volume":"31","author":"M Li","year":"2011","unstructured":"Li M, Liu J, Hu W, Jia C, Li H, Wen Z et al (2011) Effect of metformin on apoptosis of renal cell carcinoma cells in vitro and its mechanisms. Nan Fang yi ke da xue xue bao=. J South Med Univ 31(9):1504\u20131508","journal-title":"J South Med Univ"},{"issue":"9","key":"4923_CR10","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/sj.emboj.7600196","volume":"23","author":"M Koshiji","year":"2004","unstructured":"Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. Embo j 23(9):1949\u20131956","journal-title":"Embo j"},{"issue":"Pt 3","key":"4923_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/bj3480607","volume":"348","author":"MR Owen","year":"2000","unstructured":"Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(Pt 3):607\u2013614","journal-title":"Biochem J"},{"issue":"3","key":"4923_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.7150\/ijbs.29689","volume":"15","author":"M Liu","year":"2019","unstructured":"Liu M, Zhang Z, Wang H, Chen X, Jin C (2019) Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2. Int J Biol Sci 15(3):617","journal-title":"Int J Biol Sci"},{"issue":"2","key":"4923_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.clgc.2015.12.012","volume":"14","author":"JJS Cheng","year":"2016","unstructured":"Cheng JJS, Li H, Tan HS, Tan PH, Ng LG, Ng QS et al (2016) Metformin use in relation with survival outcomes of patients with renal cell carcinoma. Clin Genitourin Cancer 14(2):168\u2013175","journal-title":"Clin Genitourin Cancer"},{"issue":"11\u201312","key":"4923_CR15","doi-asserted-by":"publisher","first-page":"E687","DOI":"10.5489\/cuaj.1447","volume":"7","author":"AA Hakimi","year":"2013","unstructured":"Hakimi AA, Chen L, Kim PH, Sjoberg D, Glickman L, Walker MR et al (2013) The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. Can Urol Association J 7(11\u201312):E687","journal-title":"Can Urol Association J"},{"key":"4923_CR16","doi-asserted-by":"crossref","unstructured":"Psutka SP, Boorjian SA, Lohse CM, Stewart SB, Tollefson MK, Cheville JC et al (eds) (2015) The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Seminars and Original Investigations, Urologic Oncology2015 Feb;33(2):67.e15-23","DOI":"10.1016\/j.urolonc.2014.07.008"},{"issue":"2","key":"4923_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.clgc.2016.06.017","volume":"15","author":"L Hamieh","year":"2017","unstructured":"Hamieh L, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK (2017) Effect of metformin use on survival outcomes in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 15(2):221\u2013229","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"4923_CR18","first-page":"2823","volume":"8","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zhang X, Huang T, Geng J, Liu M, Zheng J (2015) Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma. Int J Clin Exp Pathol 8(3):2823","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"4923_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12885-018-4344-3","volume":"18","author":"M Wei","year":"2018","unstructured":"Wei M, Mao S, Lu G, Li L, Lan X, Huang Z et al (2018) Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal. BMC Cancer 18(1):434","journal-title":"BMC Cancer"},{"issue":"7","key":"4923_CR20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/genes13071211","volume":"13","author":"S-H Hong","year":"2022","unstructured":"Hong S-H, Lee K-S, Hwang H-J, Park S-Y, Han W-K, Yoon Y-E (2022) Synergic effect of metformin and everolimus on mitochondrial dynamics of renal cell carcinoma. Genes 13(7):1211","journal-title":"Genes"},{"issue":"7","key":"4923_CR21","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.21037\/tcr-2025-277","volume":"14","author":"S He","year":"2025","unstructured":"He S, Zhang B, Zhang L, Shang P, Yue Z (2025) Identification and validation of hub genes for kidney renal clear cell carcinoma treated with metformin and everolimus combination therapy. Translational Cancer Res 14(7):3943","journal-title":"Translational Cancer Res"},{"issue":"1","key":"4923_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000535025","volume":"108","author":"M Krebs","year":"2024","unstructured":"Krebs M, Kotlyar MJ, Fahl J, Janaki Raman S, R\u00f6hrig F, Marquardt A et al (2024) Metformin regulates the miR-205\/VEGFA axis in renal cell carcinoma cells: exploring a clinical synergism with tyrosine kinase inhibitors. Urol Int 108(1):49\u201359","journal-title":"Urol Int"},{"issue":"13","key":"4923_CR23","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.7150\/jca.36372","volume":"11","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Luo Q, Mo J, Li J, Ye D, Ao Z et al (2020) Metformin in combination with JS-K inhibits growth of renal cell carcinoma cells via reactive oxygen species activation and inducing DNA breaks. J Cancer 11(13):3701","journal-title":"J Cancer"},{"issue":"5","key":"4923_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.clgc.2016.04.012","volume":"14","author":"D Keizman","year":"2016","unstructured":"Keizman D, Ish-Shalom M, Sella A, Gottfried M, Maimon N, Peer A et al (2016) Metformin use and outcome of sunitinib treatment in patients with diabetes and metastatic renal cell carcinoma. Clin Genitourin Cancer 14(5):420\u2013425","journal-title":"Clin Genitourin Cancer"},{"key":"4923_CR25","doi-asserted-by":"crossref","unstructured":"Fiala O, Osta\u0161ov P, Rozsypalov\u00e1 A, Hora M, \u0160orejs O, \u0160ustr J et al (2021) Metformin use and the outcome of metastatic renal cell carcinoma treated with sunitinib or pazopanib. Cancer Manage Res 13:4077\u20134086","DOI":"10.2147\/CMAR.S305321"},{"issue":"5","key":"4923_CR26","doi-asserted-by":"publisher","first-page":"e62823","DOI":"10.1371\/journal.pone.0062823","volume":"8","author":"Z Fang","year":"2013","unstructured":"Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z et al (2013) Simvastatin inhibits renal cancer cell growth and metastasis via AKT\/mTOR, ERK and JAK2\/STAT3 pathway. PLoS ONE 8(5):e62823","journal-title":"PLoS ONE"},{"issue":"11","key":"4923_CR27","doi-asserted-by":"publisher","first-page":"9738","DOI":"10.3390\/ijms24119738","volume":"24","author":"Y-CG Lee","year":"2023","unstructured":"Lee Y-CG, Chou F-N, Tung S-Y, Chou H-C, Ko T-L, Fann YC et al (2023) Tumoricidal Activity of Simvastatin in Synergy with RhoA Inactivation in Antimigration of Clear Cell Renal Cell Carcinoma Cells. Int J Mol Sci 24(11):9738","journal-title":"Int J Mol Sci"},{"key":"4923_CR28","doi-asserted-by":"publisher","first-page":"103731","DOI":"10.1016\/j.critrevonc.2022.103731","volume":"176","author":"M Santoni","year":"2022","unstructured":"Santoni M, Monteiro FSM, Massari F, Abahssain H, Aurilio G, Molina-Cerrillo J et al (2022) Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. Crit Rev Oncol\/Hematol 176:103731","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"3","key":"4923_CR29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1080\/01635581.2016.1152383","volume":"68","author":"M Woschek","year":"2016","unstructured":"Woschek M, Kneip N, Jurida K, Marzi I, Relja B (2016) Simvastatin reduces cancerogenic potential of renal cancer cells via geranylgeranyl pyrophosphate and mevalonate pathway. Nutr Cancer 68(3):420\u2013427","journal-title":"Nutr Cancer"},{"issue":"4","key":"4923_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/21681805.2021.1876163","volume":"55","author":"Y Qiu","year":"2021","unstructured":"Qiu Y, Zhao Y, Wang H, Liu W, Jin C, Xu W (2021) Simvastatin suppresses renal cell carcinoma cells by regulating DDX5\/DUSP5. Scandinavian J Urol 55(4):337\u2013343","journal-title":"Scandinavian J Urol"},{"issue":"11","key":"4923_CR31","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/life12111890","volume":"12","author":"T-C Chen","year":"2022","unstructured":"Chen T-C, Huang C-W, Lo C-Y, Chen C-N, Chang S-F, Chen Y-Y (2022) Suppression of SREBP-1 expression by simvastatin decreases visfatin-induced chemoresistance to sunitinib in human renal carcinoma 786-O cells. Life 12(11):1890","journal-title":"Life"},{"issue":"5","key":"4923_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11523-022-00907-9","volume":"17","author":"M Santoni","year":"2022","unstructured":"Santoni M, Molina-Cerrillo J, Myint ZW, Massari F, Buchler T, Buti S et al (2022) Concomitant use of statins, metformin, or proton pump inhibitors in patients with advanced renal cell carcinoma treated with first-line combination therapies. Target Oncol 17(5):571\u2013581","journal-title":"Target Oncol"},{"issue":"32","key":"4923_CR33","doi-asserted-by":"publisher","first-page":"33046","DOI":"10.18632\/oncotarget.5422","volume":"6","author":"HJ Song","year":"2015","unstructured":"Song HJ, Lim S, Lee SJ, Lim JE, Nam D-H, Joo KM et al (2015) Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget 6(32):33046","journal-title":"Oncotarget"},{"issue":"11","key":"4923_CR34","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.3390\/cancers12113150","volume":"12","author":"SD Markowitsch","year":"2020","unstructured":"Markowitsch SD, Schupp P, Lauckner J, Vakhrusheva O, Slade KS, Mager R et al (2020) Artesunate inhibits growth of sunitinib-resistant renal cell carcinoma cells through cell cycle arrest and induction of ferroptosis. Cancers 12(11):3150","journal-title":"Cancers"},{"issue":"13Supplement","key":"4923_CR35","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1158\/1538-7445.AM2019-3805","volume":"79","author":"E Juengel","year":"2019","unstructured":"Juengel E, Markowitsch S, Erb HH, Efferth T, Haferkamp A (2019) Artesunate reduces tumor growth in sunitinb-resistant renal cell carcinoma cells. Cancer Res 2019;79(13 Suppl):Abstract 3805.","journal-title":"Cancer Res"},{"issue":"1","key":"4923_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11010-017-3052-7","volume":"435","author":"AK Chauhan","year":"2017","unstructured":"Chauhan AK, Min K-j, Kwon TK (2017) RIP1-dependent reactive oxygen species production executes artesunate-induced cell death in renal carcinoma Caki cells. Mol Cell Biochem 435(1):15\u201324","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"4923_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbrc.2017.08.097","volume":"492","author":"M Zhu","year":"2017","unstructured":"Zhu M, Li Y, Zhou Z (2017) Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage. Biochem Biophys Res Commun 492(3):373\u2013378","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4923_CR38","doi-asserted-by":"publisher","first-page":"10200","DOI":"10.1038\/s41598-021-89655-w","volume":"11","author":"JW Greenberg","year":"2021","unstructured":"Greenberg JW, Kim H, Moustafa AA, Datta A, Barata PC, Boulares AH et al (2021) Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma. Sci Rep 11(1):10200","journal-title":"Sci Rep"},{"issue":"4","key":"4923_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/15384047.2015.1018494","volume":"16","author":"A Grimaldi","year":"2015","unstructured":"Grimaldi A, Santini D, Zappavigna S, Lombardi A, Misso G, Boccellino M et al (2015) Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. Cancer Biol Ther 16(4):567\u2013579","journal-title":"Cancer Biol Ther"},{"key":"4923_CR40","doi-asserted-by":"crossref","unstructured":"Li ML, Xu YZ, Lu WJ, Li YH, Tan SS, Lin HJ et al (2024) Chloroquine potentiates the anticancer effect of sunitinib on renal cell carcinoma by inhibiting autophagy and inducing apoptosis . Oncology letters. 2018;15(3):2839-46","DOI":"10.3892\/ol.2017.7635"},{"issue":"1","key":"4923_CR41","first-page":"6631605","volume":"2021","author":"R Mao","year":"2021","unstructured":"Mao R, Shi J, Ma X, Xu H (2021) Hydroxychloroquine Potentiates Apoptosis Induced by PPAR\u03b1 Antagonist in 786-O Clear Cell Renal Cell Carcinoma Cells Associated with Inhibiting Autophagy. PPAR Res 2021(1):6631605","journal-title":"PPAR Res"},{"issue":"1","key":"4923_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3727\/096504016X14587366983838","volume":"24","author":"P Yin","year":"2016","unstructured":"Yin P, Jia J, Li J, Song Y, Zhang Y, Chen F (2016) ABT-737, a Bcl-2 selective inhibitor, and chloroquine synergistically kill renal cancer cells. Oncol Res 24(1):65","journal-title":"Oncol Res"},{"issue":"5","key":"4923_CR43","first-page":"778","volume":"50","author":"J Sun","year":"2018","unstructured":"Sun J, Song W-D, Yan S-Y, Xi Z-J (2018) Chloroquine inhibits viability of renal carcinoma cells and enhances sunitinib-induced caspase-dependent apoptosis. Beijing da xue xue bao Yi xue ban=. J Peking Univ Health Sci 50(5):778\u2013784","journal-title":"J Peking Univ Health Sci"},{"issue":"7","key":"4923_CR44","doi-asserted-by":"publisher","first-page":"e0131464","DOI":"10.1371\/journal.pone.0131464","volume":"10","author":"H-O Lee","year":"2015","unstructured":"Lee H-O, Mustafa A, Hudes GR, Kruger WD (2015) Hydroxychloroquine destabilizes phospho-S6 in human renal carcinoma cells. PLoS ONE 10(7):e0131464","journal-title":"PLoS ONE"},{"issue":"1","key":"4923_CR45","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1186\/s40064-016-3153-x","volume":"5","author":"J Zhao","year":"2016","unstructured":"Zhao J, He Q, Gong Z, Chen S, Cui L (2016) Niclosamide suppresses renal cell carcinoma by inhibiting Wnt\/\u03b2-catenin and inducing mitochondrial dysfunctions. Springerplus 5(1):1436","journal-title":"Springerplus"},{"issue":"3","key":"4923_CR46","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1159\/000490140","volume":"47","author":"X Yu","year":"2018","unstructured":"Yu X, Liu F, Zeng L, He F, Zhang R, Yan S et al (2018) Niclosamide exhibits potent anticancer activity and synergizes with sorafenib in human renal cell cancer cells. Cell Physiol Biochem 47(3):957\u2013971","journal-title":"Cell Physiol Biochem"},{"issue":"10","key":"4923_CR47","doi-asserted-by":"publisher","first-page":"030006052110443","DOI":"10.1177\/03000605211044368","volume":"49","author":"B Wang","year":"2021","unstructured":"Wang B, Ao J, Li X, Yu W, Yu D, Qiu C (2021) Doxycycline sensitizes renal cell carcinoma to chemotherapy by preferentially inhibiting mitochondrial translation. J Int Med Res 49(10):03000605211044368","journal-title":"J Int Med Res"},{"issue":"7","key":"4923_CR48","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1535-7163.MCT-13-0750","volume":"13","author":"LF Zerbini","year":"2014","unstructured":"Zerbini LF, Bhasin MK, de Vasconcellos JF, Paccez JD, Gu X, Kung AL et al (2014) Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Mol Cancer Ther 13(7):1929\u20131941","journal-title":"Mol Cancer Ther"},{"key":"4923_CR49","doi-asserted-by":"publisher","first-page":"636037","DOI":"10.3389\/fcell.2021.636037","volume":"9","author":"S Faes","year":"2021","unstructured":"Faes S, Demartines N, Dormond O (2021) Mechanistic target of rapamycin inhibitors in renal cell carcinoma: potential, limitations, and perspectives. Front cell Dev biology 9:636037","journal-title":"Front cell Dev biology"},{"issue":"16","key":"4923_CR50","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1002\/cncr.24409","volume":"115","author":"A Kapoor","year":"2009","unstructured":"Kapoor A, Figlin RA (2009) Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer: Interdisciplinary Int J Am Cancer Soc 115(16):3618\u20133630","journal-title":"Cancer: Interdisciplinary Int J Am Cancer Soc"},{"issue":"7","key":"4923_CR51","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-18-2204","volume":"25","author":"NB Haas","year":"2019","unstructured":"Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, Xu X et al (2019) Autophagy inhibition to augment mTOR inhibition: a phase I\/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma. Clin Cancer Res 25(7):2080\u20132087","journal-title":"Clin Cancer Res"},{"issue":"9637","key":"4923_CR52","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456","journal-title":"Lancet"},{"issue":"6","key":"4923_CR53","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/sj.bjc.6605868","volume":"103","author":"T Flaig","year":"2010","unstructured":"Flaig T, Costa L, Gustafson D, Breaker K, Schultz M, Crighton F et al (2010) Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer 103(6):796\u2013801","journal-title":"Br J Cancer"},{"issue":"3","key":"4923_CR54","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1046\/j.1523-1755.2003.00805.x","volume":"63","author":"FL Luan","year":"2003","unstructured":"Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M (2003) Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63(3):917\u2013926","journal-title":"Kidney Int"},{"issue":"10","key":"4923_CR55","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1002\/ijc.28579","volume":"134","author":"A Ingels","year":"2014","unstructured":"Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R et al (2014) Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer 134(10):2322\u20132329","journal-title":"Int J Cancer"},{"issue":"5","key":"4923_CR56","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/cas.14395","volume":"111","author":"K Kuroshima","year":"2020","unstructured":"Kuroshima K, Yoshino H, Okamura S, Tsuruda M, Osako Y, Sakaguchi T et al (2020) Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib\u2010resistant renal cell carcinoma. Cancer Sci 111(5):1607\u20131618","journal-title":"Cancer Sci"},{"issue":"5","key":"4923_CR57","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909\u2013918","journal-title":"J Clin Oncol"},{"issue":"14","key":"4923_CR58","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","volume":"16","author":"DC Cho","year":"2010","unstructured":"Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB et al (2010) The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16(14):3628\u20133638","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4923_CR59","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bbrc.2018.05.142","volume":"502","author":"Y-C Ou","year":"2018","unstructured":"Ou Y-C, Li J-R, Wang J-D, Chen W-Y, Kuan Y-H, Yang C-P et al (2018) Aspirin restores ABT-737-mediated apoptosis in human renal carcinoma cells. Biochem Biophys Res Commun 502(2):187\u2013193","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4923_CR60","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3233\/KCA-180027","volume":"2","author":"L Hamieh","year":"2018","unstructured":"Hamieh L, Moreira RB, Lin X, Simantov R, Choueiri TK, McKay RR (2018) Impact of Aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on outcomes in patients with metastatic renal cell carcinoma. Kidney Cancer 2(1):37\u201346","journal-title":"Kidney Cancer"},{"issue":"1","key":"4923_CR61","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.18632\/oncotarget.13774","volume":"8","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Guo J, Wang G, Chu Y, Hu X (2016) Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma. Oncotarget 2017 Jan 3;8(1):1668-1677","journal-title":"Oncotarget"},{"issue":"3","key":"4923_CR62","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/cncr.21661","volume":"106","author":"BI Rini","year":"2006","unstructured":"Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R et al (2006) Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer: Interdisciplinary Int J Am Cancer Soc 106(3):566\u2013575","journal-title":"Cancer: Interdisciplinary Int J Am Cancer Soc"},{"issue":"4","key":"4923_CR63","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s10875-011-9530-x","volume":"31","author":"A Schwandt","year":"2011","unstructured":"Schwandt A, Garcia JA, Elson P, Wyckhouse J, Finke JH, Ireland J et al (2011) Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol 31(4):690\u2013698","journal-title":"J Clin Immunol"},{"key":"4923_CR64","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jconrel.2016.11.023","volume":"246","author":"S Cazzamalli","year":"2017","unstructured":"Cazzamalli S, Dal Corso A, Neri D (2017) Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma. J Controlled Release 246:39\u201345","journal-title":"J Controlled Release"},{"issue":"12","key":"4923_CR65","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1158\/1535-7163.MCT-16-0283","volume":"15","author":"S Cazzamalli","year":"2016","unstructured":"Cazzamalli S, Dal Corso A, Neri D (2016) Acetazolamide serves as selective delivery vehicle for dipeptide-linked drugs to renal cell carcinoma. Mol Cancer Ther 15(12):2926\u20132935","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"4923_CR66","doi-asserted-by":"publisher","first-page":"14726","DOI":"10.1021\/acsomega.8b02350","volume":"3","author":"S Cazzamalli","year":"2018","unstructured":"Cazzamalli S, Figueras E, Peth\u0151 L, Borb\u00e9ly A, Steink\u00fchler C, Neri D et al (2018) In vivo antitumor activity of a novel acetazolamide\u2013cryptophycin conjugate for the treatment of renal cell carcinomas. ACS omega 3(11):14726\u201314731","journal-title":"ACS omega"},{"issue":"7","key":"4923_CR67","doi-asserted-by":"publisher","first-page":"e0236119","DOI":"10.1371\/journal.pone.0236119","volume":"15","author":"H Yoshino","year":"2020","unstructured":"Yoshino H, Yamada Y, Enokida H, Osako Y, Tsuruda M, Kuroshima K et al (2020) Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma. PLoS ONE 15(7):e0236119","journal-title":"PLoS ONE"},{"key":"4923_CR68","doi-asserted-by":"publisher","first-page":"176110","DOI":"10.1016\/j.ejphar.2023.176110","volume":"960","author":"X Ni","year":"2023","unstructured":"Ni X, Ye C, Yu X, Zhang Y, Hou Y, Zheng Q et al (2023) Overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram\/copper-induced oxidative stress and ferroptosis in renal cell carcinoma. Eur J Pharmacol 960:176110","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"4923_CR69","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2159-8290.CD-18-0957","volume":"9","author":"AA Hakimi","year":"2019","unstructured":"Hakimi AA, Voss MH, Kuo F, Sanchez A, Liu M, Nixon BG et al (2019) Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discov 9(4):510\u2013525","journal-title":"Cancer Discov"},{"issue":"1","key":"4923_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/onc.2015.99","volume":"35","author":"VW Rebecca","year":"2016","unstructured":"Rebecca VW, Amaravadi RK (2016) Emerging strategies to effectively target autophagy in cancer. Oncogene 35(1):1\u201311","journal-title":"Oncogene"},{"key":"4923_CR71","doi-asserted-by":"publisher","first-page":"217496","DOI":"10.1016\/j.canlet.2025.217496","volume":"613","author":"JS Carew","year":"2025","unstructured":"Carew JS, Espitia CM, Sureshkumar S, Carrera Espinoza MJ, Gamble ME, Wang W et al (2025) REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity. Cancer Lett 613:217496","journal-title":"Cancer Lett"},{"issue":"12","key":"4923_CR72","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1080\/15548627.2017.1377377","volume":"13","author":"S Piao","year":"2017","unstructured":"Piao S, Ojha R, Rebecca VW, Samanta A, Ma XH, McAfee Q et al (2017) ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells. Autophagy 13(12):2056\u20132071","journal-title":"Autophagy"},{"issue":"1","key":"4923_CR73","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1038\/s41598-019-40757-6","volume":"9","author":"CC Chang","year":"2019","unstructured":"Chang CC, Huang KH, Hsu SP, Lee YG, Sue YM, Juan SH (2019) Simvastatin reduces the carcinogenic effect of 3-methylcholanthrene in renal epithelial cells through histone deacetylase 1 inhibition and RhoA reactivation. Sci Rep 9(1):4606","journal-title":"Sci Rep"},{"issue":"5","key":"4923_CR75","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"1","key":"4923_CR76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A et al (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18(1):41\u201358","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4923_CR77","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00280-006-0347-x","volume":"60","author":"MK Krzyzanowska","year":"2007","unstructured":"Krzyzanowska MK, Tannock IF, Lockwood G, Knox J, Moore M, Bjarnason GA (2007) A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol 60(1):135\u2013141","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"4923_CR78","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston DR, Davis M (2017) Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies. Clin Cancer Res 23(14):3489\u20133498","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4923_CR79","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1142\/S0192415X25500922","volume":"53","author":"J Li","year":"2025","unstructured":"Li J, Zheng J, Cui Y, Liu Y, Fan H, Wang X et al (2025) The Role of Artesunate in Cancer Management: Mechanisms of Biomedical Effects and Toxicology. Am J Chin Med 53(8):2489\u20132512","journal-title":"Am J Chin Med"},{"issue":"4","key":"4923_CR80","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Motzer RJ (2017) Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med 376(4):354\u2013366","journal-title":"N Engl J Med"},{"key":"4923_CR81","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M et al (2017) Renal cell carcinoma. Nat Rev Dis Primers 3:17009","journal-title":"Nat Rev Dis Primers"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04923-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04923-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04923-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:02:58Z","timestamp":1784617378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04923-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4923"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04923-8","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"80"}}